Anti-Glutaminyl cyclase antibody (ab201172)
Key features and details
- Rabbit polyclonal to Glutaminyl cyclase
- Suitable for: IHC-P, WB
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Glutaminyl cyclase antibody -
Description
Rabbit polyclonal to Glutaminyl cyclase -
Host species
Rabbit -
Tested applications
Suitable for: IHC-P, WBmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Cow -
Immunogen
Recombinant fragment corresponding to Human Glutaminyl cyclase aa 150-350.
Database link: Q16769 -
Positive control
- HepG2 and Jurkat cell line lysate. Human thyroid tissue.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Lyophilized:Reconstitute in 200 uL sterile distilled water -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.20
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Positive Controls
-
Recombinant Protein
-
Related Products
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab201172 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
IHC-P |
1/100 - 1/500.
|
|
WB |
1/200 - 1/1000. Predicted molecular weight: 41 kDa.
|
Notes |
---|
IHC-P
1/100 - 1/500. |
WB
1/200 - 1/1000. Predicted molecular weight: 41 kDa. |
Target
-
Function
Responsible for the biosynthesis of pyroglutamyl peptides. Has a bias against acidic and tryptophan residues adjacent to the N-terminal glutaminyl residue and a lack of importance of chain length after the second residue. Also catalyzes N-terminal pyroglutamate formation. In vitro, catalyzes pyroglutamate formation of N-terminally truncated form of APP amyloid-beta peptides [Glu-3]-beta-amyloid. May be involved in the N-terminal pyroglutamate formation of several amyloid-related plaque-forming peptides. -
Sequence similarities
Belongs to the glutaminyl-peptide cyclotransferase family. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 281437 Cow
- Entrez Gene: 25797 Human
- Entrez Gene: 70536 Mouse
- Omim: 607065 Human
- SwissProt: Q28120 Cow
- SwissProt: Q16769 Human
- SwissProt: Q9CYK2 Mouse
- Unigene: 79033 Human
see all -
Alternative names
- 5730422A13Rik antibody
- EC antibody
- GCT antibody
see all
Images
-
Immunohistochemical analysis of formalin fixed, paraffin embedded human thyroid tissue labeling Glutaminyl cyclase with ab201172 at a 1/100 dilution.
-
All lanes : Anti-Glutaminyl cyclase antibody (ab201172) at 1/500 dilution
Lane 1 : HepG2 cell line lysate
Lane 2 : Jurkat cell line lysate
Predicted band size: 41 kDa
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (3)
ab201172 has been referenced in 3 publications.
- Zhao T et al. QPCT regulation by CTCF leads to sunitinib resistance in renal cell carcinoma by promoting angiogenesis. Int J Oncol 59:N/A (2021). PubMed: 34036385
- Wang X et al. Glutaminyl cyclase inhibitor exhibits anti-inflammatory effects in both AD and LPS-induced inflammatory model mice. Int Immunopharmacol 75:105770 (2019). PubMed: 31377588
- Zhao T et al. DNA methylation-regulated QPCT promotes sunitinib resistance by increasing HRAS stability in renal cell carcinoma. Theranostics 9:6175-6190 (2019). PubMed: 31534544